Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative procedure for a
variety of hematologic malignancies. The field has evolved substantially over the past …

The goal of treatment for multiple myeloma (MM) is to improve patients' long-term outcomes.
One important factor that has been associated with prolonged progression-free and overall …

Purpose We investigated the effect on minimal residual disease, by qualitative and real-time
quantitative polymerase chain reaction (RQ-PCR), of a consolidation regimen that included …

Allogeneic haematological stem cell transplantation (HSCT) has developed into
immunotherapy. Donor CD4+, CD8+ and natural killer (NK) cells have been reported to …

Autologous stem cell transplantation (ASCT) is considered the gold standard in the frontline
therapy of younger patients with multiple myeloma because it results in higher complete …

Melphalan remains the most widely used agent in preparative regimens for hematopoietic
stem cell transplantation (SCT). From its initial discovery more than 50 years ago, it has …

Before the introduction of new drugs, we designed a trial where treatment of newly
diagnosed myeloma patients was based on the presence or absence of HLA-identical …

Therapeutic options for multiple myeloma (MM) patients have changed quickly in recent
years and uncertainty has arisen about optimal approaches to therapy. A reasonable goal of …

Allogeneic hematopoietic stem cell transplantation (alloHSCT) is increasingly being used for
treatment of hematologic malignancies, and the immunologic graft-versus-tumor effect (GVT) …

Simple Summary The aim of this review is to provide an overview of the current scientific
evidence concerning the role of stem cell transplantation in multiple myeloma. During the …